Frank Holden Mose

Frank Holden Mose

Auto-generated profile, based on publicly available information

Frank Holden Mose

Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
TLThomas Larsen
Thomas Larsen
FMFrank H. Mose
Frank H. Mose
JBJesper Nørgaard Bech
Jesper Nørgaard Bech
AHAnnebirthe Bo Hansen
Annebirthe Bo Hansen
EPErling B. Pedersen
Erling B. Pedersen
Background. Low 25-hydroxy-vitamin D (25(OH)D) levels are inversely related to blood pressure (BP) and have been associated with incident hypertension.

5 June 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
LBLouise A. Beveridge
Louise A. Beveridge
FKFaisel Khan
Faisel Khan
ASAllan D. Struthers
Allan D. Struthers
JAJane Armitage
Jane Armitage
Ilaria BarchettaIlaria Barchetta
Ilaria Barchetta
MWMiles D. Witham
Miles D. Witham
Background: Low 25‐hydroxyvitamin D levels are associated with an increased risk of cardiovascular events, but the effect of vitamin D supplementation on markers of vascular function associated with major adverse cardiovascular events is unclear. Methods and Results: We conducted a systematic review and individual participant meta‐analysis to examine the effect of vitamin D supplementation on flow‐mediated dilatation of the brachial artery, pulse wave velocity, augmentation index, central blood pressure, microvascular function, and reactive hyperemia index. MEDLINE, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, and http://www.ClinicalTrials.gov were searched until the end of 2016 without language restrictions. Placebo‐controlled randomized trials of at least 4 weeks duration were included. Individual participant data were sought from investigators on included trials. Trial‐level meta‐analysis was performed using random‐effects models; individual participant meta‐analyses used a 2‐stage analytic strategy, examining effects in prespecified subgroups. 31 trials (2751 participants) were included; 29 trials (2641 participants) contributed data to trial‐level meta‐analysis, and 24 trials (2051 participants) contributed to individual‐participant analyses. Vitamin D3 daily dose equivalents ranged from 900 to 5000 IU; duration was 4 weeks to 12 months. Trial‐level meta‐analysis showed no significant effect of supplementation on macrovascular measures (flow‐mediated dilatation, 0.37% [95% confidence interval, −0.23 to 0.97]; carotid‐femoral pulse wave velocity, 0.00 m/s [95% confidence interval, −0.36 to 0.37]); similar results were obtained from individual participant data. Microvascular function showed a modest improvement in trial‐level data only. No consistent benefit was observed in subgroup analyses or between different vitamin D analogues. Conclusions: Vitamin D supplementation had no significant effect on most markers of vascular function in this analysis.

24 March 2014 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
FMFrank H Mose
Frank H Mose
HVHenrik Vase
Henrik Vase
TLThomas Larsen
Thomas Larsen
AKAnne Sp Kancir
Anne Sp Kancir
RKRenata Kosierkiewic
Renata Kosierkiewic
EPErling B Pedersen
Erling B Pedersen
Patients on chronic dialysis are at increased risk of vitamin D deficiency. In observational studies plasma 25-hydroxyvitamin D (p-25(OH) D) levels are inversely correlated with plasma BNP and adverse cardiovascular outcomes. Whether a causal relation exists has yet to be established. The aim of this study was to test the hypothesis that cholecalciferol supplementation improves cardiac function and reduces blood pressure (BP) and pulse wave velocity (PWV) in patients on chronic dialysis.

26 July 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
TLThomas Larsen
Thomas Larsen
FMFrank H Mose
Frank H Mose
JBJesper Nørgaard Bech
Jesper Nørgaard Bech
EPErling B Pedersen
Erling B Pedersen
Vitamin D receptor activators reduce albuminuria, and may improve survival in chronic kidney disease (CKD). Animal studies suggest that these pleiotropic effects of vitamin D may be mediated by suppression of renin. However, randomized trials in humans have yet to establish this relationship.

1 June 2018 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
ASAnne Sophie Koldkjær Sølling
Anne Sophie Koldkjær Sølling
BTBirgitte G Tougaard
Birgitte G Tougaard
THTorben Harsløf
Torben Harsløf
BLBente Langdahl
Bente Langdahl
HBHelle Kongsbak Brockstedt
Helle Kongsbak Brockstedt
LRLars Rejnmark
Lars Rejnmark
Introduction: Injection of paraffin oil to augment muscles size is a troubling phenomenon known to cause a foreign body reaction with formation of granulomas. In a few case reports, long-term side effects have been reported in terms of hypercalcemia and renal failure.Methods: We identified a case series of 12 male bodybuilders presenting with non-parathyroid hypercalcemia who previously had injected paraffin oil to increase muscles size.Results: At admission, all patients had moderate-to-severe hypercalcemia with suppressed PTH levels and impaired renal function. Calcitriol levels were within the normal range or slightly elevated. Follow-up measurements showed marked hypercalciuria with nearly normal levels of bone turnover markers. A correlation was found between levels of peptidyl dipeptidase and calcitriol (R = 0.812,P = 0.050). Treatment with antiresorptive agents seemed less effective than glucocorticoids, which resulted in a significantly lowering of ionized calcium levels and improved renal function, although no patients were cured by this treatment. Immunosuppression with azathioprine or mycophenolate may have a glucocorticoid-saving effect. One patient had surgery with removal of affected muscle tissue, without any apparent effect on plasma calcium levels.Conclusion: The hypercalcemia and associated hypercalciuria seems to be due to an intestinal hyperabsorption of calcium. It remains to be elucidated, whether an increased calcitriol synthesis within granulomas is the only (main) mechanism by which intestinal calcium absorption is increased. Glucocorticoids seem most appropriate as the first choice for treatment. Bodybuilders should be warned against use of intramuscular oil injections (and other substances), as this may have severe adverse health consequences.

1 August 2017 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
JRJeppe Bakkestroem Rosenbaek
Jeppe Bakkestroem Rosenbaek
STSafa Al Therwani
Safa Al Therwani
JJJanni Majgaard Jensen
Janni Majgaard Jensen
FMFrank Holden Mose
Frank Holden Mose
CWChristine Wandall-Frostholm
Christine Wandall-Frostholm
JBJesper Nørgaard Bech
Jesper Nørgaard Bech
Sodium nitrite (NaNO2) is converted to nitric oxide (NO) in vivo and has vasodilatory and natriuretic effects. Our aim was to examine the effects of NaNO2on hemodynamics, sodium excretion, and glomerular filtration rate (GFR). In a single-blinded, placebo-controlled, crossover study, we infused placebo (0.9% NaCl) or 0.58, 1.74, or 3.48 μmol NaNO2·kg−1·h−1for 2 h in 12 healthy subjects, after 4 days of a standard diet. Subjects were supine and water loaded. We measured brachial and central blood pressure (BP), plasma concentrations of renin, angiotensin II, aldosterone, arginine vasopressin (P-AVP), and plasma nitrite (P-[ ]), GFR by Cr-EDTA clearance, fractional excretion of sodium (FENa) free water clearance (CH2O), and urinary excretion rate of guanosine 3′,5′-cyclic monophosphate (U-cGMP). The highest dose reduced brachial systolic BP (5.6 mmHg, P = 0.003), central systolic BP (5.6 mmHg, P = 0.035), and CH2O(maximum change from 3.79 to 1.27 ml/min, P = 0.031) and increased P-[ ] (from 0.065 to 0.766 μmol/l, P < 0.001), while reducing U-cGMP (from 444 to 247 pmol/min, P = 0.004). GFR, FENa, P-AVP, and the components in the renin-angiotensin-aldosterone system did not change significantly. In conclusion, intravenous NaNO2induced a dose-dependent reduction of brachial and central BP. The hemodynamic effect was not mediated by the renin-angiotensin-aldosterone system. NaNO2infusion resulted in a vasopressin-independent decrease in CH2Oand urine output but no change in urinary sodium excretion or GFR. The lack of increase in cGMP accompanying the increase in [ ] suggests a direct effect of nitrite or nitrate on the renal tubules and vascular bed with little or no systemic conversion to NO.